Berlin Cures GmbH

What Berlin Cures GmbH does

Berlin Cures GmbH is a private, for-profit biotechnology company headquartered in Zug, Switzerland, founded in 2014. According to the company's own description, it operates a "unique platform technology" and develops therapeutic products "based on scientific findings that may help suffering patients," indicating a science-driven, platform-based approach to drug or therapy development rather than a single-asset model.

The company operates with a small team of 11-50 employees and is led by CEO Oliver Von Stein and COO Dr. Peter Göttel, suggesting a lean organization focused on research and early-stage development rather than large-scale commercialization. No specific therapeutic indications, modalities, pipeline assets, clinical trial stages, or platform mechanism details are disclosed in the available source material, so the precise scientific focus (e.g., cardiovascular, immunology, rare disease) cannot be characterized from the data provided.

The business model is not explicitly described in the input — there is no disclosed pricing, go-to-market motion, customer segmentation, or revenue stream information. Given the pre-commercial profile typical of platform biotech at this headcount, revenue would likely be expected to come from future licensing, partnerships, or product commercialization rather than current sales; however, the source data does not confirm any of these mechanics. The broader source block also contains significant noise from an unrelated entity (SPY777, an online gambling platform) that has no bearing on Berlin Cures and was disregarded.

Name

Berlin Cures GmbH

Website

https://berlincures.de

Company type

Private

Founded year

2014

Headcount range

11–50 employees

Short description

Berlin Cures GmbH is a privately held Swiss biotechnology company, founded in 2014 and based in Zug, that operates a proprietary platform technology to develop therapeutic products based on scientific findings aimed at helping suffering patients.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• Platform biotechnology
• Therapeutic development
• Drug discovery
• Biopharmaceutical research
• Scientific platform technology

Headquarters

HQ city

Zug

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Berlin Cures develops therapeutic products based on a unique proprietary platform technology, applying scientific findings to create treatments intended to help suffering patients. The company is headquartered in Zug, Switzerland, and operates as a privately held biotechnology firm founded in 2014.

Differentiator

Problem solved

Functional benefit

Products and services

• Proprietary Platform Technology Unique platform technology that serves as the foundation for developing therapeutic products based on scientific findings intended to help suffering patients. Berlin Cures leverages this platform to generate its pipeline of candidates.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights1 record

Broad incumbents

• Wave Life Sciences: Clinical-stage nucleic-acid therapeutics company with programs in genetic and cardiometabolic diseases; comparable as an oligonucleotide-platform peer with similar modality and development stage.
• Ionis Pharmaceuticals: Established leader in antisense oligonucleotide drug discovery and development; relevant as a broad incumbent in nucleic-acid therapeutics with cardiovascular pipeline exposure.
• Bayer (Cardiovascular Division): Large pharmaceutical company with significant cardiovascular and heart-failure commercial franchises; relevant as a potential strategic acquirer/partner and incumbent in the same end indications.

Direct peers

• Aptamer Group: UK-based developer of Optimer aptamer binders for therapeutics and diagnostics; directly comparable as an aptamer-platform company pursuing therapeutic applications.
• Cardior Pharmaceuticals: German clinical-stage biotech developing RNA-based therapeutics for heart failure and cardiovascular disease; directly comparable to Berlin Cures in indication focus, European origin, and nucleic-acid/biologic modality.
• Noxxon Pharma: European clinical-stage company developing Spiegelmer aptamers to neutralize disease-related targets; closely comparable in aptamer/oligonucleotide platform technology and clinical-stage development model.
• Silence Therapeutics: London-listed biotech developing siRNA and other nucleic-acid therapeutics for cardiovascular and rare diseases; directly comparable in nucleic-acid modality and cardiovascular focus.

Regional players

• Imara (now part of Enliven Therapeutics): Cardiovascular-focused clinical-stage biotech (historically pursuing heart failure); relevant as a comparable late-stage/clinical-stage peer in the same therapeutic area.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat1 record

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/berlin-cures-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Berlin Cures GmbH